Publications

(* represents equal contribution)

Published Papers (PDFs)

  1. Schor S, Pu S, Nicolaescu V, Azari S, Kõivomägi M, Karim M, Cassonnet P, Saul S, Neveu G, Yueh A, Demeret C, Skotheim JM, Jacob Y, Randall G, Einav S.  The cargo adapter protein CLINT1 is phosphorylated by the Numb-associated kinase BIKE and mediates dengue virus infection. J Biol Chem. 2022 Apr 20;298(6):101956. doi: 10.1016/j.jbc.2022.101956. Online ahead of print.PMID: 35452674.
  2. Yiran E. Liu*, Sirle Saul*, Aditya Manohar Rao, Makeda Lucretia Robinson, Olga Lucia Agudelo Rojas, Ana Maria Sanz, Michelle Verghese, Daniel Solis, Mamdouh Sibai, Chun Hong Huang, Malaya Kumar Sahoo, Rosa Margarita Gelvez, Nathalia Bueno, Maria Isabel Estupiñan Cardenas, Luis Angel Villar Centeno, Elsa Marina Rojas Garrido, Fernando Rosso, Michele Donato, Benjamin A. Pinsky, Shirit Einav* and Purvesh Khatri*. An 8-gene machine learning model improves clinical prediction of severe dengue progression Genome Medicine (2022) 14:33https://doi.org/10.1186/s13073-022-01034-w
  3. Marwah Karim, Sirle Saul,  Luca Ghita,  Malaya Kumar Sahoo, Chengjin Ye, Nishank Bhalla, Jing Jin, Jun-Gyu Park, Belén Martinez-Gualda, Michael Patrick East, Gary L. Johnson,  Benjamin A. Pinsky, Luis Martinez-Sobrido, Christopher R. M. Asquith, Aarthi Narayanan, Steven De Jonghe, Shirit Einav. Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for therapy. doi: https://doi.org/10.1101/2022.03.18.484178 Preprint. BioRxiv
  4. Pei-Tzu Huang, Shirit Einav and Christopher R. M. Asquith. PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders. Nat Rev Drug Discov. 2021 Oct;20(10):730. doi: 10.1038/d41573-021-00158-9. PMID: 34504321. DOI: 10.1038/d41573-021-00158-9
  5. Sirle Saul, Pei-Tzu Huang, Shirit Einav, Christopher R M Asquith. Evaluation and identification of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV). Bioorg Med Chem Let. 2021 Oct 5;128407. doi: 10.1016/j.bmcl.2021.128407. PMID: 34624490. DOI: 10.1016/j.bmcl.2021.128407
  6. Saul S, Karim M, Huang PT, Ghita L, Chiu W, Kumar S, Bhalla N, Leyssen P, Cohen CA, Huie K, Tindle C, Sibai M, Pinsky BA, Das S, Ghosh P, Dye JM, Solow-Cordero DE, Jin J, Jochmans D, Neyts J, Narayanan A, De Jonghe S, Einav S. Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen. bioRxiv. 2021 Jun 15:2021.05.15.444128. doi: 10.1101/2021.05.15.444128. PMID: 34159337
  7. Yao Z, Zanini F, Kumar S, Karim M, Saul S, Bhalla N, Panpradist N, Muniz A, Narayanan A, Quake SR, Einav S. The transcriptional landscape of Venezuelan equine encephalitis virus (TC-83) infection. PLoS Negl Trop Dis. 2021 Mar 31;15(3):e0009306. doi: 10.1371/journal.pntd.0009306. eCollection 2021 Mar. PMID: 33788849
  8. Martinez-Gualda B, Saul S, Froeyen M, Schols D, Herdewijn P, Einav S, De Jonghe S. Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase. Eur J Med Chem. 2021 Mar 5;213:113158. doi: 10.1016/j.ejmech.2021.113158. Epub 2021 Jan 12. PMID: 33497888
  9. BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals. Pu S, Schor S, Karim M, Saul S, Robinson M, Kumar S, Prugar LI, Dorosky DE, Brannan J, Dye JM, Einav S. Antiviral Res. 2020 Dec;184:104966. doi: 10.1016/j.antiviral.2020.104966. Epub 2020 Nov 1. PMID: 33137362
  10. Saul, S. & Einav, S. (2020). Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. ACS infectious diseases. 2020 Aug 10. DOI: 10.1021/acsinfecdis.0c00343. PMID: 32687696. PMCID: PMC7416635 (Invited Perspective)
  11. Saul, S., Pu, S.-Y., Zuercher, W. J., Einav, S. & Asquith, C. R. M. Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines. Bioorganic & medicinal chemistry letters, 127284, doi:https://doi.org/10.1016/j.bmcl.2020.127284 (2020).
  12. Durham ND, Agrawal A, Waltari E, Croote D, Zanini F, Fouch M, Davidson E, Smith O, Carabajal E, Pak JE, Doranz BJ, Robinson M, Sanz AM, Albornoz LL, Rosso F, Einav S, Quake SR, McCutcheon KM, Goo L. Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics. eLife. 2019 Dec 10;8. pii: e52384. doi: 10.7554/eLife.52384. PMID:31820734
  13.  Martinez-Gualda, B, Pu S, Froeyen M, Herdewijn P, Einav, S, De Jonghe S. Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase. Bioorganic & medicinal chemistry. 2019 Nov 11:115188. doi: 10.1016/j.bmc.2019.115188. PMID: 31757682
  14. Robinson, M.L. and Einav, S. (2019). Towards predicting progression to severe dengue. Trends in Microbiology. 2020 Jan 22. pii: S0966-842X(19)30318-X. doi: 10.1016/j.tim.2019.12.003. PMID:31982232 (Invited Review)
  15. Verdonck S*, Pu, SY*, Sorrell FJ, Elkins JM, Froeyen M, Gao LJ, Prugar LI, Dorosky DE, Brannan JM, Barouch-Bentov R, Knapp S, Dye JM, Herdewijn P, Einav S**, De Jonghe S**. Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity. Journal of medicinal chemistry. 2019 Jun 27;62(12):5810-5831. doi: 10.1021/acs.jmedchem.9b00136. Epub 2019 Jun 12.
  16. Kumar S*, Barouch-Bentov R*, Xiao F, Schor S, Pu S, Biquand E, Lindenbch B, Jacob Y, Demeret C, and Einav S. MARCH8 ubiquitinates the hepatitis C virus nonstructural 2 protein and mediates viral envelopment. Cell Reports. 2019 Feb 12;26(7):1800-1814.e5. doi: 10.1016/j.celrep.2019.01.075. PMID: 30759391.
  17. Robinson M, Sweeney T, Barouch-Bentov R., Sahoo MK, Sanz A, Isabel E, Albornoz L, Rosso F, Montoya GJ, Pinsky B, Khatri P*, and Einav S. A 20-gene set predictive of progression to severe dengue. Cell Reports. 2019 Jan 29; 26(5):1104-1111.e4. doi: 10.1016/j.celrep.2019.01.033. PMID: 30699342.
  18. Zanini, F., Robinson, M. L., Croote, D., Sahoo, M. K., Sanz, A. M., Ortiz-Lasso, E., Albornoz, L. L., Rosso, F., Montoya, J. G., Goo, L., Pinsky, B. A., Quake, S. R., Einav, S. Virus-inclusive single-cell RNA sequencing reveals the molecular signature of progression to severe dengue. Proc Natl Acad Sci U S A. 2018 Dec 7. pii: 201813819. doi: 10.1073/pnas.1813819115.
  19. Wouters R, Pu SY, Froeyen M, Lescrinier E, Einav S, Herdewijn P, De Jonghe S. Cyclin G-associated kinase (GAK) affinity and antiviral activity studies of a series of 3-C-substituted isothiazolo[4,3-b]pyridines. Eur J Med Chem. 2018 Nov 28;163:256-265. doi: 10.1016/j.ejmech.2018.11.065.PMID: 30529544.
  20. Robinson M, Schor S, Barouch-Bentov R, and Einav S. Viruses and the intracellular roads more travelled by. Cellular and Molecular Life Sciences. 2018 July 24. doi.org/10.1007/s00018-018-2882-0
  21. Wouters R, Pu S, Schor S, Barouch-Bentov R, Brannan J, Dye J, Herdewijn P, De Jonghe S and Einav S. Optimization of isothiazolo[4,3-b]pyridines-based inhibitors of cyclin G associated kinase (GAK) with broad-spectrum antiviral activity. Journal of Medicinal Chemistry. 2018 June 28.(DOI: 10.1021/acs.jmedchem.8b00613)
  22. Pu S, Xiao F, Schor S, Bekerman E, Fabio Z, Barouch-Bentov R, Nagamine C and Einav S. Feasbility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Research. Volume 155, July 2018, Pages 67–75. 
  23. Barouch-Bentov R and Einav S. Turning Up Your Nose for a Flaviviral Encephalitis Cure. Cell Host & Microbe. 2018 Volume 23 , Issue 4 , 427 - 429
  24. Xiao F, Shulla A, Wang S, Pu S, Neveu G, Beer M, Schor S, Barouch-Bentov R, Randall G, and Einav S. Interactions between the nonstructural 2 protein and host adaptor proteins 1 and 4 orchestrate hepatitis C virus release. mBio. 2018 Mar 13;9(2). pii: e02233-17. doi: 10.1128/mBio.02233-17.
  25. Zanini F*, Pu S*, Bekerman E, Einav S**, and Quake SR**. Single-cell transcriptional dynamics of flavivirus infection. eLife. Feb 2018.
  26. Schor S and Einav S. Combating intracellular pathogens with repurposed host-targeted drugs. American Chemical Society Infectious Diseases. 2018 Jan 3. doi: 10.1021/acsinfecdis.7b00268. [Epub ahead of print]. PMID: 29298032.
  27. Schor S and Einav S. Repurposing kinase inhibitors as broad-spectrum antiviral drugs. DNA and Cell Biology. 2017 Nov 17. doi: 10.1089/dna.2017.4033. PMID: 29148875.
  28. Bekermnan E*, Neveu G*, Shulla A, Brannan J, Pu SZ, Wang S, Xiao F, Barouch-Bentoc R, Bakken RR, Mateo R, Govero J, Nagamine C, Diamond M, De Jonghe S, Herdewijn P, Dye J, Randall G, and Einav S. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. Journal of Clinical Investigation. 2017 Feb 27. PMID: 28240606
  29. Barouch-Bentov R, Neveu G, Xia F, Beer M, Bekerman E, Schor S, Campbell J, Boonyaratanakornkit J, Lindenbach B, Lu A, Jacob Y, Einav S. Hepatitis C Virus Proteins Interact with the Endosomal Sorting Complex Required for Transport (ESCRT) Machinery via Ubiquitination To Facilitate Viral Envelopment. mBio. 2016 Nov 1;7(6). PMID: 27803188, PMCID: PMC5090039
  30. Glick Y,  Ben-Ari Y,  Drayman N, Pellach M, Neveu G, Boonyaratanakornkit J, Avrahami D, Einav S, Oppenheim A, Gerber D. Pathogen Receptor Discovery with a Microfluidic Human Membrane Protein Array. Proceedings of the National Academy of Sciences. 2016 Apr 19;113(16):4344-9. doi: 10.1073/pnas.1518698113. PMID: 27044079, PMCID: PMC4843447. 
  31. Plissonnier ML, Lahlali T, Michelet M, Lebossé F, Cottarel J, Beer M, Neveu G, Durantel D, Bartosch B, Accardi R, Clément S, Paradisi A, Devouassoux M, Einav S, Mehlen P, Zoulim F, Parent R. Epidermal Growth Factor Receptor-dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus. PLoS Biology. 2016 Mar 31;14(3):e1002421. doi: 10.1371/journal.pbio.1002421. PMID: 27031829. PMCID: PMC4816328.
  32. Li K, Kovackova S, Pu S, Rozenski J, De Jonghe S, Einav S, and Herdewijn P. Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase: synthesis, structure–activity relationship studies and antiviral activity. Medicinal Chemistry Communications. 2015 Aug.  
  33. Bekerman E, Einav S. Response—Applying antibiotics lessons to antivirals. Science. 2015 Jun 26; 348(6242):1437. PMID: 26113710.
  34. Bekerman E, Einav S. Combating Emerging Viral Threats. Science. 2015; 348(6232):282-3. PMID: 25883340.
  35. Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S. AP-2-Associated Protein Kinase 1 and Cyclin G-Associated Kinase Regulate Hepatitis C Virus Entry and Are Potential Drug Targets. Journal of Virology. 2015; 89(8):4387-404. PMID: 25653444.
  36. Kovackova S, Chang L, Bekerman E, Neveu G, Barouch-Bentov R, Chaikuad A, Heroven C, Šála M, De Jonghe S, Knapp S, Einav S, Herdewijn P. Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents. Journal of Medicinal Chemistry. 2015; PMID: 25822739.
  37. Ng PP, Kuo CC, Wang S, Einav S, Aracaini L, Portlock CS, Marcotrigiano J, Tarr A, Ball J, Levy , and Levy S. B Cell Receptors Expressed by Lymphomas of Hepatitis C virus-Infected Patients Rarely React with the Viral Proteins. Blood. 2014 Jan 21. Epub. PMID: 24449209.
  38. Neveu G*, Barouch-Bentov R*,  Ziv-Av A, Gerber D, Jacob Y, and Einav S. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathogens. 2012 Aug 16; 8 (8): e1002845. PMID: 22916011.
  39. Einav S, Dvory-Sobol H, Gehrig H and Glenn JS. The Hepatitis C virus (HCV) NS4B RNA Binding Inhibitor, Clemizole, is Highly Synergistic with HCV Protease Inhibitors. Journal of Infectious Diseases. 2010 Jul 1;202(1):65-74. PMID: 20486856.
  40. Bryson BD, Cho NJ, Einav S, Lee CH, Tai V, Bechtel J, Sivaraja M, Roberts C, Schmitz U, Glenn JS. Small Molecule Inhibits HCV Replication and Disrupts NS4B Subcellular Localization. Antiviral Research. 2010 Apr 2. PMID: 20363257.
  41. Parameswaran P, Sklan HE, Burgon T, Samuel MA, Wilkins C, Lu R, Ansel KM,  Heissmeyer V, Einav S, Jackson W, Doukas T, Paranjape S, Polacek C, dos Santos FB, Jalili R, Babrzadeh F, Gharizadeh B, Grimm D, Kay M, Sarnow P, Ronaghi M, Ding SW, Harris E,  Chow M, Diamond MS, Kirkegaard K, Glenn JS, and Fire A. 6 RNA VIRUSES & 41 HOSTS: vsRNAs And Viral Modulation of Small Rna Repertoires in Vertebrate and Invertebrate Systems. PLoS Pathogens. 2010 Feb 12;6(2):e1000764. PMID: 20169186.
  42. Einav S*, Gerber D*, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR. Discovery of a Hepatitis C Target and its Pharmacological Inhibitors by Microfluidic Affinity Analysis. Nature Biotechnology. 2008 Sept 26 (9): 1019-27. PMID: 18758449. (+Journal Cover).
  43. Einav S, Sklan H E, Moon E, Gehrig E, Liu P, Hao Y, Lowe AW and Glenn JS.  The Nucleotide Binding Motif of Hepatitis C Virus NS4B Can Mediate NIH3T3 Transformation and Tumor Formation in the Absence of Activated Ha-ras Co-Transfection. Hepatology. 2008 Mar 47(3):827-35. PMID: 18081150.
  44. Sklan EH, Serrano RL, Einav S, Pfeffer SR, Lambright DG, Glenn JS. TBC1D20 is a Rab1 GAP that Mediates HCV Replication. Journal of Biological Chemistry. 2007 Dec 14; 282(50):36354-61. PMID: 17901050.
  45. Einav S*, Elazar M*, Danieli T, and Glenn JS. A Nucleotide Binding Motif in HCV NS4B Mediates HCV RNA Replication. Journal of Virology. 2004 Oct 78 (20):11288-95. PMID: 15452248.
  46. Einav S, Glenn JS. Prenylation Inhibitors: a Novel Class of Antiviral Agents. Journal of Antimicrobial Chemotherapy. 2003 November; 52: 883-886. Review. PMID: 14613953.
  47. Einav S, Koziel MJ. Immunopathogenesis of Hepatitis C in the Immunosuppressed host. Transplant Infectious Disease. 2002 June; 4(2):85-92. Review. PMID: 12220245.
  48. Einav S, Pozdnyakova OO, Ma M, Carroll MC. Complement C4 is Protective for Lupus Disease Independent of C3. Journal of Immunology. 2002 Feb 1;168(3):1036-41. PMID: 11801636.

Book Chapters

Barouch-Bentov R, Jacob Y, Einav S.Screening of Interactions with the ESCRT Machinery by a Gaussia princeps Split Luciferase-Based Complementation Assay. Methods in molecular biology (Clifton, N.J.) 2019; 1998: 291–304.

Shafer RW, Einav S and Chou S (2007). Mechanisms of Resistance to Antiviral Agents. In Manual of Clinical Microbiology, 9th Edition, Murray PR ed, Baron EJ ed, Jorgensen JH ed, Pfaller MA ed, Tenover FC ed, and Yolken RH ed. American Society of Microbiology. 1689-04.

Patents

De Jonghe S, Herdewijn P and Einav S. PCT filing, co-owned by Stanford and University of Leuven/Belgium, is currently pending. Antiviral use of GAK-modulators.

Einav S, Barouch-Bentov R, Neveu G, and Zivav A. Methods and compositions for treating viral diseases. WO 2013/086133.

Einav S, Barouch-Bentov R, Neveu G. Methods and compositions for treating enveloped viruses. US-2017-0136021-A1 (WO2016054468 A1).

Einav S, Glenn JS, Mcdowell R, Yang W. US 8895598. 2014 November 25. Methods of treating a Flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection. 

Glenn JS, Einav S. US 8871435. 2014 October 28. Methods and compositions for identifying agents that inhibit an NS4B-mediated neoplastic cellular phenotype of HCV infected cells

Einav S, Glenn JS, Mcdowell R, Yang W, Dvory-Sobol H. US 8895598. Nov 25th 2014. Methods of Treating a Flaviviridae Family Viral Infection, Compositions for Treating a Flaviviridae Family Viral Infection, and Screening Assays for Identifying Compositions for Treating a Flaviviridae Family Viral Infection.

Einav S, Glenn JS, Yang W, Dvory-Sobol H, Choong IC, McDowell R. US 20100028299. 2010 February 04. Methods and compositions of treating a flaviviridae family viral infection

Einav S, Glenn JS, Yang W, Dvory-Sobol H, Choong IC, McDowell R. US 20100015093. 2010 January 21. Methods and compositions of treating a flaviviridae family viral infection

Einav S, Glenn JS, McDowell R, Yang W, Dvory-Sobol H. US 20110052536. 2011 March 03. Methods of treating a flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infection

Glenn JS, Einav S, Elazar M. US 20100203498. 2010 August 12. Methods and compositions for identifying anti-hcv agents.

Glenn JS, Einav S, Elazar M. United States US 7582428. 2009 September 01. Methods and compositions for identifying anti-HCV agents